{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360576122193678976.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/1878-0261.12202"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1878-0261.12202"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12202"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/1878-0261.12202"}},{"identifier":{"@type":"URI","@value":"https://febs.onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12202"}}],"dc:title":[{"@value":"<scp>ANP</scp>32E induces tumorigenesis of triple‐negative breast cancer cells by upregulating E2F1"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>Triple‐negative breast cancer (<jats:styled-content style=\"fixed-case\">TNBC</jats:styled-content>) lacks expression of estrogen receptor (<jats:styled-content style=\"fixed-case\">ER</jats:styled-content>), progesterone receptor, and the <jats:styled-content style=\"fixed-case\">HER</jats:styled-content>2 receptor; it is highly proliferative and becomes the deadliest forms of breast cancer. Effective prognostic methods and therapeutic targets for <jats:styled-content style=\"fixed-case\">TNBC</jats:styled-content> are required to improve patient outcomes. Here, we report that acidic nuclear phosphoprotein 32 family member E (<jats:styled-content style=\"fixed-case\">ANP</jats:styled-content>32E), which promotes cell proliferation in mammalian development, is highly expressed in <jats:styled-content style=\"fixed-case\">TNBC</jats:styled-content> cells compared to other types of breast cancer. High expression of <jats:styled-content style=\"fixed-case\">ANP</jats:styled-content>32E correlates significantly with worse overall survival (OS; <jats:italic>P </jats:italic><<jats:italic> </jats:italic>0.001) and higher risks of disease recurrence (<jats:italic>P </jats:italic><<jats:italic> </jats:italic>0.001) in patients with <jats:styled-content style=\"fixed-case\">TNBC</jats:styled-content>. Univariate and multivariate Cox‐regression models show that <jats:styled-content style=\"fixed-case\">ANP</jats:styled-content>32E is an independent prognostic factor in <jats:styled-content style=\"fixed-case\">TNBC</jats:styled-content>. Furthermore, we discovered that <jats:styled-content style=\"fixed-case\">ANP</jats:styled-content>32E promotes tumor proliferation <jats:italic>in vitro</jats:italic> by inducing G1/S transition, and <jats:styled-content style=\"fixed-case\">ANP</jats:styled-content>32E inhibition suppresses tumor formation <jats:italic>in vivo</jats:italic>. By examining the expression of E2F1, cyclin E1, and cyclin E2, we discovered that <jats:styled-content style=\"fixed-case\">ANP</jats:styled-content>32E promotes the G1/S transition by transcriptionally inducing E2F1. Taken together, our study shows that <jats:styled-content style=\"fixed-case\">ANP</jats:styled-content>32E is an efficient prognostic marker, and it promotes the G1/S transition and induces tumorigenesis of <jats:styled-content style=\"fixed-case\">TNBC</jats:styled-content> cells by transcriptionally inducing E2F1.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380576122193678982","@type":"Researcher","foaf:name":[{"@value":"Zhenchong Xiong"}],"jpcoar:affiliationName":[{"@value":"Department of Breast Surgery State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678981","@type":"Researcher","foaf:name":[{"@value":"Liping Ye"}],"jpcoar:affiliationName":[{"@value":"Department of Experimental Research State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678976","@type":"Researcher","foaf:name":[{"@value":"He Zhenyu"}],"jpcoar:affiliationName":[{"@value":"Department of Radiation Oncology State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678980","@type":"Researcher","foaf:name":[{"@value":"Fengyan Li"}],"jpcoar:affiliationName":[{"@value":"Department of Radiation Oncology State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678979","@type":"Researcher","foaf:name":[{"@value":"Yahui Xiong"}],"jpcoar:affiliationName":[{"@value":"The First College of Clinical Medicine Southern Medical University Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678986","@type":"Researcher","foaf:name":[{"@value":"Chuyong Lin"}],"jpcoar:affiliationName":[{"@value":"Department of Experimental Research State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678984","@type":"Researcher","foaf:name":[{"@value":"Xianqiu Wu"}],"jpcoar:affiliationName":[{"@value":"Department of Experimental Research State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678983","@type":"Researcher","foaf:name":[{"@value":"Guangzheng Deng"}],"jpcoar:affiliationName":[{"@value":"Department of Breast Surgery State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678978","@type":"Researcher","foaf:name":[{"@value":"Wei Shi"}],"jpcoar:affiliationName":[{"@value":"Department of Medical Oncology State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678987","@type":"Researcher","foaf:name":[{"@value":"Libing Song"}],"jpcoar:affiliationName":[{"@value":"Department of Experimental Research State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678985","@type":"Researcher","foaf:name":[{"@value":"Zhongyu Yuan"}],"jpcoar:affiliationName":[{"@value":"Department of Medical Oncology State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]},{"@id":"https://cir.nii.ac.jp/crid/1380576122193678977","@type":"Researcher","foaf:name":[{"@value":"Xi Wang"}],"jpcoar:affiliationName":[{"@value":"Department of Breast Surgery State Key Laboratory of Oncology in Southern China Collaborative Innovation Center for Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"15747891"},{"@type":"EISSN","@value":"18780261"}],"prism:publicationName":[{"@value":"Molecular Oncology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2018-04-18","prism:volume":"12","prism:number":"6","prism:startingPage":"896","prism:endingPage":"912"},"reviewed":"false","dc:rights":["http://creativecommons.org/licenses/by/4.0/"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1878-0261.12202"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12202"},{"@id":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/1878-0261.12202"},{"@id":"https://febs.onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12202"}],"createdAt":"2018-04-10","modifiedAt":"2023-09-17","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360857593781874304","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"TRIM39 is a poor prognostic factor for patients with estrogen receptor‐positive breast cancer and promotes cell cycle progression"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/1878-0261.12202"},{"@type":"CROSSREF","@value":"10.1111/pin.13190_references_DOI_PuKM36PVQIm5KaQHZwLhe88mqXs"}]}